SARS-CoV-2 Spike Protein (RBD) (E2T6M) Mouse Monoclonal Antibody#69323,Cell Signaling Technology (CST),69323
SARS-CoV-2 Spike Protein (RBD) (E2T6M) Mouse Monoclonal Antibody recognizes endogenous levels of total SARS-CoV-2 spike protein. This antibody detects full-length protein, and also detects the S1 fragment generated by furin cleavage. This antibody does not cross-react with spike proteins from SARS or MERS coronaviruses.
Host
Mouse
Reactivity
Virus
Application
Western Blotting: 1:1000
Platform ID
BAB756393752
.png)
Cell Signaling Technology (CST)
Contact
Tel: 877-616-2355,978-867-2388
Fax: 877-616-2355
Email:
Specifications
Scientific Background
The cause of the COVID-19 pandemic is a novel and highly pathogenic coronavirus, termed SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). SARS-CoV-2 is a member of the Coronaviridae family of viruses (1). The genome of SARS-CoV-2 is similar to other coronaviruses, and is comprised of four key structural proteins: S, the spike protein, E, the envelope protein, M, the membrane protein, and N, the nucleocapsid protein (2). Coronavirus spike proteins are class I fusion proteins and harbor an ectodomain, a transmembrane domain, and an intracellular tail (3,4). The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases at S1/S2 and S2’ sites. S1 and S2 subunits remain associated after cleavage and assemble into crown-like homotrimers (2,4). In humans, both SARS-CoV and SARS-CoV-2 spike proteins utilize the angiotensin-converting enzyme 2 (ACE2) protein as a receptor for cellular entry (5-7). Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors (8,9).Zhou, P. et al. (2020)Nature579, 270-3.Tortorici, M.A. and Veesler, D. (2019)Adv Virus Res105, 93-116.Li, F. et al. (2006)J Virol80, 6794-800.Li, F. (2016)Annu Rev Virol3, 237-61.Shang, J. et al. (2020)Nature581, 221-4.Wrapp, D. et al. (2020)Science367, 1260-3.Yan, R. et al. (2020)Science367, 1444-8.Yuan, Y. et al. (2017)Nat Commun8, 15092.Amanat, F. and Krammer, F. (2020)Immunity52, 583-9.Alternate Names2019-nCoV surface glycoprotein; Peplomer protein; S glycoprotein; SARS-CoV-2 spike protein; spike glycoprotein; SPIKE_SARS2; surface glycoprotein
Synonyms
2019-nCoV surface glycoprotein; Peplomer protein; S glycoprotein; SARS-CoV-2 spike protein; spike glycoprotein; SPIKE_SARS2; surface glycoprotein
Category Paths
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.
